Imunon Inc Dossier
Qualitative Analysis
Business overview
Imunon, Inc. (formerly Celsion Corporation) is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. The company is developing its non-viral DNA technology across two primary platforms: TheraPlas® for the gene-based delivery of cytokines and other therapeutic proteins to treat solid tumors, and PlaCCine® for the gene delivery of viral antigens to elicit strong immunological responses. Imunon's lead clinical program is IMNN-001 (formerly GEN-1), a DNA-based immunotherapeutic drug candidate designed for the localized treatment of advanced ovarian cancer. IMNN-001 works by intraperitoneally administering an IL-12 plasmid formulated with the proprietary TheraPlas delivery system, instructing the body to produce cancer-fighting molecules directly at the tumor site.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A corporate restructuring announced on February 5, 2026, designed to eliminate headcount not essential to the Phase 3 trial and redefine job descriptions to reduce operating expenses.
Expected impact: Lowers general and administrative overhead, allowing the company to focus its financial resources primarily on the pivotal OVATION 3 Phase 3 clinical trial.
Focusing clinical development resources on the Phase 3 OVATION 3 study evaluating IMNN-001 in combination with standard-of-care chemotherapy for newly diagnosed advanced ovarian cancer.
Expected impact: Aims to establish IMNN-001 as the first frontline treatment in advanced ovarian cancer to show a clinically meaningful overall survival benefit, leading to a BLA filing.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides critical non-dilutive or structured cash financing to extend the company's operating runway and fund the ongoing Phase 3 OVATION 3 clinical trial.
Terms: Up to $10 million in cash financing, closed on June 3, 2026.